Stocks Bristol-Myers Squibb Co

More

  • Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • U.S. stock futures were lower this morning, ahead of the prospect for greater volatility and volume on the final Friday of the year for quadruple witching.

  • LONDON, Dec 16- Bristol-Myers Squibb's closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain's cost watchdog. However, the head of Britain's leading cancer research center said companies needed to do more to bring down the cost of such...

  • LONDON, Dec 16- Bristol-Myers Squibb's closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain's cost watchdog. In draft guidance issued on Wednesday, the National Institute for Health and Care Excellence said using Opdivo in non-small...

  • The "Fast Money" traders give their final trades of the day.

  • FRANKFURT, Dec 9- European and U.S. drug regulators are looking into whether a defective blood clotting test device affected a trial involving Bayer's top-selling anti-clotting drug Xarelto, hitting the German drugmaker's shares. "Due to the defect it is now thought that the INR device may have impacted the clotting results in some patients in the warfarin...

  • BERLIN, Dec 9- European and U.S. drug regulators are looking into whether a defective blood-clotting test device affected a trial involving Bayer's blockbuster anti-blood clotting drug Xarelto, hitting the German drugmaker's shares. Bayer and Duke University's Clinical Research Institute, which conducted some of the trial work and which used the device in...

  • LONDON, Dec 4- The cost of cancer drugs varies substantially across Europe, experts said on Friday in a new analysis that is likely to fuel debate about the rising cost of modern medicines. But there are also wide gaps in Europe, according to Wim van Harten of the Netherlands Cancer Institute and colleagues, writing in the journal Lancet Oncology.

  • Nov 30- The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone.

  • Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Mad Money Lightning Round

    Jim Cramer quickly gives his take to caller favorite stocks at lightning speed, including this play on commodities.

  • Trader on the floor of the New York Stock Exchange.

    Earnings news, especially from Apple, could stir up a market that's waiting for the Fed.

  • A trader signals an offer in a Treasury note options pit at the CME Group in Chicago.

    U.S. sovereign bonds traded higher on Monday ahead of the Federal Reserve's two-day policy meeting this week and a raft of major corporate earnings.

  • The "Halftime Report" traders give their top trades of the show.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stock index futures indicated a flat to mildly lower open as traders prepare for the Fed's two-day meeting this week and a slew of earnings.

  • Jim Cramer on the set of Mad Money

    “Mad Money” host Jim Cramer takes the time to reveal the stocks that are running away from the competition.

  • Apple's iPhone 6 are displayed as people browse through products at a store in Atlantic City, New Jersey.

    Jim Cramer cannot believe what a stellar week of earnings this was. Now that the bar is set so high, he warned that Apple could get hurt next week.

  • Traders work on the floor of the New York Stock Exchange.

    Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.

  • Prescription drugs

    Voter initiatives in California and Ohio to control prescription med prices have ramifications for the presidential contest.

  • The "Fast Money" traders give their final thoughts of the day.